Alveolar Hemorrhage in ANCA-associated Vasculitis: Results of an International, Randomized, Controlled Trial (PEXIVAS)

Lynn A Fussner,Luis Felipe Flores-Suárez,Rodrigo Cartin-Ceba,Ulrich Specks,P Gerard Cox,David R W Jayne,Peter A Merkel,Michael Walsh,Lynn A. Fussner,P. Gerard Cox,David R. W. Jayne,Peter A. Merkel

DOI: https://doi.org/10.1164/rccm.202308-1426oc

IF: 24.7

2024-02-12

American Journal of Respiratory and Critical Care Medicine

Abstract:RATIONALE: Diffuse alveolar hemorrhage (DAH) is a life-threatening manifestation of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). The Plasma Exchange (PLEX) and Glucocorticoids (GC) in Severe AAV (PEXIVAS;NCT00987389) trial was the largest in AAV and first to enroll participants with DAH requiring mechanical ventilation.OBJECTIVES: Evaluate characteristics, treatment effects, outcomes for patients with AAV with and without DAH.METHODS: PEXIVAS randomized 704 participants to PLEX or no-PLEX and reduced or standard-dose GC. DAH status was defined at enrollment as no-DAH, non-severe, or severe (room air SpO₂≤85% or use of mechanical ventilation).MEASUREMENTS AND MAIN RESULTS: At enrollment, 191(27.1%) participants had DAH (61 severe, including 29 ventilated) and were younger, more frequently relapsing, PR3-ANCA positive, and had lower serum creatinine but were more frequently dialyzed than participants without DAH (n=513,72.9%). Among those with DAH, 8/95(8.4%) receiving PLEX died within one year vs. 15/96(15.6%) with no-PLEX (HR 0.52,CI 0.21-1.24), while 13/96(13.5%) receiving reduced-GC died vs. 10/95(10.5%) with standard-GC (HR 1.33,CI 0.57-3.13). When ventilated, ventilator-free days were similar with PLEX vs. no-PLEX (medians 25,IQR 22-26 vs. 22-27), fewer with reduced-GC (23[20-25]) vs. standard-GC (26[25-28]). Treatment effects on mortality did not vary by presence or severity of DAH. Overall, 23/191(12.0%) with DAH died within one year vs. 34/513(6.6%) without DAH. End-stage kidney disease and serious infections did not differ by DAH status or treatments.CONCLUSION: Patients with AAV and DAH differ from those without DAH in multiple ways. Further data are required to confirm or refute a benefit of PLEX or GC dosing on mortality. Clinical trial registration available at www.CLINICALTRIALS: gov, ID: NCT00987389.

respiratory system,critical care medicine